BioVaria 2013: 14-3-3 platform technology against numerous diseases
On 4 June the BioVaria technology fair will be the market place for life science inventions from leading European research institutions and universities for the 6th time in Munich. Under the motto “Europe’s Next Top Technologies” numerous licensable technologies will be presented by the scientists. Max-Planck-Innovation together with the Lead Discovery Center (LDC) will introduce a novel 14-3-3 platform technology, originating from the Max Planck Institute of Molecular Physiology and the Chemical Genomics Centre, to an audience from the biotech- and pharmaceutical- as well as the venture capital sectors.
Picture: BioVaria fair at Sofitel Munich Bayerpost
14-3-3 proteins regulate a multitude of enzymes and proteins, some of which play prominent roles in the development of cancer, in apoptosis and in neurodegenerative diseases, amongst other things. Binding to 14-3-3 proteins can either inhibit or stimulate a proteins function as has been shown for specific phosphatases or the tumor suppressor protein p53, respectively. Depending on the physiological context, the stabilization of a regulatory 14-3-3 protein-protein complex might be of high therapeutic value, for example in various cancers. Small molecule stabilizers of these therapeutically interesting interactions unlock the potential to address a number of so far “undruggable” targets. The commercial opportunity of this novel platform technology is enormous, since 14-3-3 proteins have not been addressed as drug targets so far. Therefore, “Stabilizing” instead of “Inhibiting” is an innovative approach in drug discovery, opening an entirely new dimension to the field of small molecule research. The 14-3-3 platform technology turns protein/protein interactions and so called non-druggable targets into druggable ones.
The proof of principle of the innovative 14-3-3 platform technology has been shown for one herbicide and three oncology targets. Based on these innovative targets numerous novel compounds have been identified for further optimization. Several projects are being currently pursued at the LDC or together with leading pharma companies. The most advanced sub-projects are currently in the hit-to-lead phase.
More information about the technology and the BioVaria technology fair can be found under http://www.biovaria.org/technologies_details